DH
Definitive Healthcare Corp.
DH trails on the overall score without a compensating advantage in the available component scores.
OSCR
Oscar Health, Inc.
OSCR has the edge over DH overall, supported by stronger fundamentals and lower modeled downside.
DH Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Stable | |
| Weak |
DH's cash flow is currently stable, but its revenue, profitability and balance sheet are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
DH PE Valuation
DH has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
DH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect DH's profitability to improve, with its earnings and revenue holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over DH on the outlook, with more favorable earnings and revenue expectations.
DH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.19 | — |
| Q3 2026 | -$1.55 | +$0.14 |
| Q2 2026 | -$1.65 | +$1.02 |
| Q1 2026 | -$1.67 | +$2.74 |
| Q4 2025 | -$1.30 | +$2.24 |
| Q3 2025 | -$1.69 | +$1.42 |
| Q2 2025 | -$2.67 | +$0.82 |
| Q1 2025 | -$4.41 | -$2.65 |
| Q4 2024 | -$3.54 | -$1.75 |
DH is still losing money, but far less than before: $1.55 per share over the past year, against $4.41 at its worst in early 2025.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over DH on earnings quality, reporting a profit while its opponent remains loss making.
DH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.7M | -9% |
| Q2 2026 | $55.2M | -9.1% |
| Q1 2026 | $55.9M | -5.5% |
| Q4 2025 | $61.5M | -1.2% |
| Q3 2025 | $60M | -4.2% |
| Q2 2025 | $60.8M | -4.7% |
| Q1 2025 | $59.2M | -6.8% |
| Q4 2024 | $62.3M | -5.5% |
DH's revenue has slid since its 2023 peak: $55M last quarter, down 9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -9.1% | +5.4 points |
| Q2 2026 | -12% | -5.4 points |
| Q1 2026 | -360% | -48 points |
| Q4 2025 | -43% | +117 points |
| Q3 2025 | -14% | +345 points |
| Q2 2025 | -6.9% | +573 points |
| Q1 2025 | -312% | -287 points |
| Q4 2024 | -160% | -145 points |
DH's operating margin was −9.1% last quarter, up 5.4 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over DH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over DH on profitability, with a higher operating margin.
DH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $9M | -33% |
| Q2 2026 | $8.5M | +21% |
| Q1 2026 | $8.4M | -54% |
| Q4 2025 | -$1.7M | +$1M |
| Q3 2025 | $13.4M | -28% |
| Q2 2025 | $7M | -49% |
| Q1 2025 | $18.4M | +12% |
| Q4 2024 | -$2.8M | -167% |
DH still generates free cash flow, though less than at its 2024 peak: $24M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over DH on cash flow, with more consistent year-over-year improvement.
DH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +957K shares |
| 1 year | +2.9% | +3M shares |
| 3 years | -6.8% | -7.8M shares |
| 5 years | +21% | +18.5M shares |
| Available history | -9.8% | -11.5M shares |
DH has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $9.2M |
| Q2 2025 | $19.1M |
| Q1 2025 | $21.2M |
| Q4 2024 | $7.3M |
DH hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
DH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2021 | 8.5x | High |
| Q1 2021 | 0.5x | Very low |
| Q4 2020 | 8.9x | High |
DH's net debt is about 8.5 years of its operating earnings (EBITDA).
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
DH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.1 | Neutral |
| Stochastic | 86.0 | Overbought |
DH's weekly RSI is 60 (neutral) and its Stochastic is 86 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
DH PE vs Healthcare Sector
DH has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
DH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.06 | 18% above |
| 20 week MA | $0.91 | 37% above |
| 50 week MA | $1.26 | 0.8% below |
| 100 week MA | $2.43 | 49% below |
| 200 week MA | $5.21 | 76% below |
DH has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 76% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over DH on trend strength, trading above more of its moving averages.
DH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $49.0 | $28.4 | -42% |
| 2022 | $28.4 | $11.4 | -60% |
| 2023 | $11.4 | $9.94 | -13% |
| 2024 | $9.94 | $4.23 | -57% |
| 2025 | $4.23 | $2.63 | -38% |
| 2026 YTD | $2.63 | $1.25 | -52% |
DH has finished every year since 2021 lower, and it's down 52% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over DH on returns for 2026, with the stronger performance.